November 11th, 2026Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCLA meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.Read more
November 9th, 2026FDA Flashback: Hematologic Cancer Decisions and News From October 2026Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.Read more